TASK DEFINITION: Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
PROBLEM: Context: We have dreams almost every night. Do you ever notice the colors of your dreams? Do you dream in black and white or do you dream in yellow, red and green? New research suggests that the type of television you watched as a child has a great effect on the color of your dreams. While almost all people under 25 dream in color, thousands of people over 55, all of whom were brought up with black and white TV sets, often dream in monochrome . "It suggests there could be a critical period in our childhood when watching films has a big impact on the way dreams are formed", said Eva Murzyn, a psychology student at Dundee University in Britain who carried out the study. Research from 1915 through the 1950s suggested that the vast majority of dreams are in black and white. But the tide turned in the sixties, and later results suggested that up to 83 percent of dreams contain some color. Since this period also marked the transition between black-and-white film and TV and Technicolor ,an obvious explanation was that the media had been painting people's dreams. However, there weren't any firm conclusions. But now Miss Murzyn believes she has proven the link. She made a survey of more than 60 people, half of whom were over 55 and half of whom were under 25. She asked the volunteers to answer a questionnaire on the color of their dreams and their childhood exposure to film and TV. She then analyzed her own data. Only 4.4 percent of the under-25s' dreams were black and white. The over-55s who had had access to color TV and film during their childhood also reported a very low proportion of just 7.3 percent. But the over-55s who only had access to black-and -white media reported dreaming in black and white about a quarter of the time. Even though they would have spent only a few hours a day watching TV or films, their attention and emotion would have been heightened during this time, leaving a deeper imprint on their mind, Miss Murzyn told the New Scientist. "The crucial time is between three and ten when we all begin to have the ability to dream", she said. 
 Question: In which magazine can you find the article?

SOLUTION: new scientist

PROBLEM: Context: Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males by core symptoms that include non-verbal status, intellectual disability, epilepsy, truncal ataxia, postnatal microcephaly and hyperkinesis. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. The extent and variability of the CS phenotype in female heterozygotes, who presumably express the wild-type and mutant SLC9A6 alleles mosaically as a result of X-chromosome inactivation (XCI), have not yet been systematically characterized. Slc9a6 knockout mice (Slc9a6 KO) were generated by insertion of the bacterial lacZ/-galactosidase (-Gal) reporter into exon 6 of the X-linked gene. Mutant Slc9a6 KO male mice have been shown to develop late endosomal/lysosomal dysfunction associated with glycolipid accumulation in selected neuronal populations and patterned degeneration of Purkinje cells (PCs). In heterozygous female Slc9a6 KO mice, -Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype. Using -Gal, we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice. At the behavioral level, we showed that heterozygous female mice suffer from visuospatial memory and motor coordination deficits similar to but less severe than those observed in X-chromosome hemizygous mutant males. Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group. 
 Question: Mutation of which gene is implicated in the Christianson syndrome?

SOLUTION: slc9a6

PROBLEM: Context: Interleukin-1 (IL-1) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1 antibody being developed as a treatment for diseases in which IL-1 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1 signaling through an allosteric mechanism. Because IL-1 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1 to its receptor by altering the electrostatic surface potential of IL-1, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1 signaling that may offer an alternative to current therapies for IL-1-associated autoinflammatory diseases. 
 Question: Which molecule is targeted by the drug Gevokizumab?

SOLUTION:
il-1β